These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17760807)

  • 1. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma.
    Rendtlew Danielsen JM; Knudsen LM; Dahl IM; Lodahl M; Rasmussen T
    Br J Haematol; 2007 Sep; 138(6):756-60. PubMed ID: 17760807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
    Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
    Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.
    Kumar S; Rajkumar SV; Kyle RA; Lacy MQ; Dispenzieri A; Fonseca R; Lust JA; Gertz MA; Greipp PR; Witzig TE
    J Clin Oncol; 2005 Aug; 23(24):5668-74. PubMed ID: 16110026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes.
    Girlanda S; Fortis C; Belloni D; Ferrero E; Ticozzi P; Sciorati C; Tresoldi M; Vicari A; Spies T; Groh V; Caligaris-Cappio F; Ferrarini M
    Cancer Res; 2005 Aug; 65(16):7502-8. PubMed ID: 16103105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
    Pérez-Persona E; Mateo G; García-Sanz R; Mateos MV; de Las Heras N; de Coca AG; Hernández JM; Galende J; Martín-Nuñez G; Bárez A; Alonso JM; Martín A; López-Berges C; Orfao A; San Miguel JF; Vidriales MB
    Br J Haematol; 2010 Jan; 148(1):110-4. PubMed ID: 19821821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
    Bacher U; Haferlach T; Kern W; Alpermann T; Schnittger S; Haferlach C
    Cancer Genet Cytogenet; 2010 Dec; 203(2):169-75. PubMed ID: 21156229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between clonal plasma cells and the immune system in plasma cell dyscrasias.
    Perez-Andres M; Almeida J; Martin-Ayuso M; Moro MJ; Garcia-Marcos MA; Moreno I; Dominguez M; Galende J; Heras N; Gonzalez MI; San Miguel JF; Orfao A;
    J Biol Regul Homeost Agents; 2004; 18(2):161-5. PubMed ID: 15471221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
    Sezer O; Heider U; Zavrski I; Possinger K
    Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.
    Scavelli C; Nico B; Cirulli T; Ria R; Di Pietro G; Mangieri D; Bacigalupo A; Mangialardi G; Coluccia AM; Caravita T; Molica S; Ribatti D; Dammacco F; Vacca A
    Oncogene; 2008 Jan; 27(5):663-74. PubMed ID: 17667938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden.
    Feyler S; von Lilienfeld-Toal M; Jarmin S; Marles L; Rawstron A; Ashcroft AJ; Owen RG; Selby PJ; Cook G
    Br J Haematol; 2009 Mar; 144(5):686-95. PubMed ID: 19133978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment.
    Pérez-Andrés M; Almeida J; Martín-Ayuso M; Moro MJ; Martín-Nuñez G; Galende J; Borrego D; Rodríguez MJ; Ortega F; Hernandez J; Moreno I; Domínguez M; Mateo G; San Miguel JF; Orfao A; ;
    Leukemia; 2005 Mar; 19(3):449-55. PubMed ID: 15674420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma.
    Greipp PR; Lust JA
    Stem Cells; 1995 Aug; 13 Suppl 2():10-21. PubMed ID: 8520496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.
    De Bruyne E; Bos TJ; Asosingh K; Vande Broek I; Menu E; Van Valckenborgh E; Atadja P; Coiteux V; Leleu X; Thielemans K; Van Camp B; Vanderkerken K; Van Riet I
    Clin Cancer Res; 2008 May; 14(10):2918-26. PubMed ID: 18483358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of thrombospondin-1(TSP-1) and its binding partners, CD36 and CD47, in sporadic inclusion body myositis.
    Salajegheh M; Raju R; Schmidt J; Dalakas MC
    J Neuroimmunol; 2007 Jul; 187(1-2):166-74. PubMed ID: 17572512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should bone marrow examination be routinely performed for the diagnosis of monoclonal gammopathy of undetermined significance?
    Elis A; Radnay J; Shapiro H; Itzhaky D; Manor Y; Lishner M
    Isr Med Assoc J; 2006 Dec; 8(12):840-2. PubMed ID: 17214099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
    Martín P; Santón A; García-Cosío M; Bellas C
    Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.
    Liebisch P; Eppinger S; Schöpflin C; Stehle G; Munzert G; Döhner H; Schmid M
    Haematologica; 2005 Apr; 90(4):489-93. PubMed ID: 15820944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology.
    Cannizzo E; Bellio E; Sohani AR; Hasserjian RP; Ferry JA; Dorn ME; Sadowski C; Bucci JJ; Carulli G; Preffer F
    Cytometry B Clin Cytom; 2010 Jul; 78(4):231-8. PubMed ID: 20198608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells.
    Bernal M; Garrido P; Jiménez P; Carretero R; Almagro M; López P; Navarro P; Garrido F; Ruiz-Cabello F
    Hum Immunol; 2009 Oct; 70(10):854-7. PubMed ID: 19580833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.
    Taylor BJ; Reiman T; Pittman JA; Keats JJ; de Bruijn DR; Mant MJ; Belch AR; Pilarski LM
    J Immunother; 2005; 28(6):564-75. PubMed ID: 16224274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.